Patent Application
20200087697
The present invention relates to a method for modifying glycoproteins so that the glycoproteins comprise one or more tri-mannosyl cores. The present invention also relates to glycoprotein-payload conjugates, which comprise the glycoprotein of the invention and a payload of interest.
Therapeutic protein drugs have been widely used in clinic, and due to their advantages of high value, high specificity and low toxicities, some of big pharmaceutical companies in the world devote themselves in the development of this category of drugs to clinical trials. Most of these therapeutic proteins are monoclonal antibodies. Even though some of patients are satisfied with their clinical outcomes, the clinical trial data suggest that the therapeutic effects of some of these antibodies still need lo be improved, particularly, in cancer treatments. To solve this disadvantage, scientists start to focus on modifying these clinical antibodies so as to improve their efficacies in the cancer therapy by some technologies. Among these technologies, antibody-drug conjugates (ADCs) draw more attentions due to their chemistry, manufacturing and control (CMC) friendly, user friendly, and lower side effects. So far, there are 4 therapeutic antibody-drug conjugates available in the market, including Mylotarg®, Adcentris®, Besponsa® and Kadcyla®; many are others are under development (Kubizek F1, Eggenreich B1, Spadiut O1. Protein Pept Lett. 2017, 24(8):686-695; Fischer E., Roger Schibli R. Antibodies 2015, 4, 197-224; Sapra, P., Hooper, A., O'Donnell, C. and Gerber, H.-P. Expert Opin. Investig. Drugs 2011, 20, 1131-1180; Flygare, J., Pillow, T. and Aristoff. P., Chem. Biol. Drug Des. 2013, 81, 113-121, Panowski, S.; Bhakta, S., Raab. H.; Polakis, P. and Junutula, J. R. Site-specific antibody drug conjugates for cancer therapy. MAbs 2013, 6, 34-45).
In these clinical ADC's, Kadcyla and Mylotarg are formed by randomly conjugating a payload or linker t amine groups of lysine residues, however. Adcetris®, brentuximab vedotin (cAC10-vcMMAE, SGN-35), is a chimeric anti-CD30 monoclonal antibody with the fusion of the variable heavy and light region of the murine anti-CD30 antibody AC10. An average of 4 (2-8) MMAE molecules are conjugated to the SGN-30 scaffold. The conjugated points of MMAE are random —SH groups of cysteine residues produced by mild reduction of the inter-chain disulfide bonds. The linker consists of a thiol-reactive maleimidocaproyl spacer, the dipeplide valine-citrulline linker, and a PABC spacer (Francisco J A, Cerveny C G, Meyer D L, Mixan B J, Klussman K, Chace D F, Rejniak S X et al. cAC10-vcMMAE Blood 2003, 4, 1458-65). Although such technologies easily conjugate a payload or linker to an antibody, due to the problems of the multiple lysine sequences and the optimal reaction of reduction cysteine residues in an antibody, it is difficult for these two technologies to control the drug-to-antibody ratio (DAR) of the conjugates. These phenomena always cause the heterogeneity of antibody products and induce CMC problems. Some literatures even indicate that this type of first generation non site-specific ADC has disadvantages of PK and immunogenicity.
To solve these disadvantages of first generation ADC, site-specific ADC platforms are developed including SMART-Tag, non-nature ammo acid any tyrosine, therapeutic sortase, Thio-Bridge, etc. As we expect, these technologies are capable of generating homogeneous ADC products by engineering some specific sites or domains in parent antibodies. For example the Thio-Bridge technology connects the linker and the payload to the partially reduced disulfide bonds of antibodies. The SMART-Tag is a technology by mutating the adjacent sequence of an antibody as a substrate sequence of bacteria oxidase. The resulting product with formaldehydes is used as the connect site of linker and payload. As expected these second generation ADC technologies are able to generate ADC products with unique DARs and high homogeneity. However, due to the mutation of nature antibodies, the ADC products may have PK and immunogenicity problems. Presently, the conjugation of a payload to an antibody through N-glycosylation is drawn a lot of attentions due to the successful development of glycolengineering of antibodies.
All naturally occurring IgGs and recombinant antibodies have an ammo acid asparagine at position 297 (Asn297) in each of the heavy chain CH2 constant regions which is an N-glycosylation site. By the glycosylation and post modification in mammalian cells, two di-antenna-shaped glycan moieties are formed through the N-glycosylation on an IgG, and each of the di-antenna-shaped glycan moieties is basically constructed by at least 7 sugar moieties having the following formula:
in which a first GlcNAc (GlcNAc1) respectively bonds to Asn297 of the antibody and a second GlcNAc (GlcNAc2), and optionally a fucose sugar (Fuc); GlcNAc2 further bonds to a first mannose (Man1); a second and a third mannose (Man2 and Man3) respectively bond to the α-1,3 and α-1,6 positions of Man1; and two further GlcNAc sugars (GlcNAc3 and GlcNAc4) respectively bond to the β-1,2 positions of Man2 and Man3. An antibody having such glycan moieties with Fucose represented as G0F, however, when the fucose moiety is absent, the antibody is G0. (T. Shantha Raju MAbs. 2012 May 1; 4(3): 385-391). When either GlcNAc3 or GlcNAc4 bonds to an additional galacytose sugar, the antibody is represented as G1F/G1 antibody. When both the terminal GlcNAc sugars in the glycan moiety of an antibody respectively bond to two additional galacytose sugars, the antibody is represented as G2F/G2 antibody. Antibodies produced by mammalian cells generally mas include G0F (more than about 40%), G1F (about 30%-40%) and G2F (less than 1%), and a very small amount of G1F/G1 and G2F/G2 linking to sialic acid.
Because engineering each branching site in the N297 glycans maintains the structure intact and creates some functional diversity, for example ADCC, half life and CDC, of antibodies, some N297 glycoengineering ADC platforms have been developed and some of products are in the clinical trial stage. WO 2014/164534 A2, WO 2014/065661 A1, WO 2015/032899 A1, WO 2015/057064 A1, WO 2015/157446 A1, U.S. Pat. Nos. 8,716,033 B2, 7,416,858 B2, EP 2753752 B3 and a review article (Bioconjug Chem.; 2015 Nov. 18; 26(11):2070-5) have disclosed many modified glycan moieties for antibody drug conjugations. However, the drug antibody ratios (DAR) in an antibody-drug conjugation cannot be well controlled and the payload diversity cannot be performed in these technologies, and thus there is a need in the art for controlling the drug antibody ratio and increasing payload diversity of an ADC. The invention fulfills that need and provides other benefits.
One aspect of the invention provides a process for producing a glycoprotein-payload conjugate comprising a structure of formula (1):
Another aspect of the invention provides a process for producing a glycoprotein-payload conjugate comprising a structure of formula (5):
Another aspect of the invention provides a process for producing a glycoprotein-payload A/B conjugate comprising a structure of formula (7)
Another aspect of the invention provides glycoprotein-payload conjugates obtainable by the processes of the invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications and patents specifically mentioned herein are incorporated by reference for all purposes including describing and disclosing the chemicals, cell lines, vectors, animals, instruments, statistical analysis and methodologies which are reported in the publications which might be used in connection with the invention. All references cited in this specification are to be taken as indicative of the level of skill in the art.
ADC antibody-drug conjugate
DAR drug-to-antibody ratio
Asn asparagine
GlcNAc N-acetylglucosamine
GlcNAz N-azidoacetylglucosamine
Fuc fucose
Man mannose
MGAT-1; GnT-1 mannosyl (□-1,3-)-glycoprotein □-1,2-N-acetylglucosaminyltransferase
MGAT-2; GnT-2 mannosyl (□1,6-)-glycoprotein □-1,2-N-acetylglucosaminyltransferase
UDP uridine diphosphate
DBCO dibenzocyclooctyne group
DM1 mertansine
PEG polyethylene glyco
MES 4-morpholineethanesulfonic acid
MMAE monomethyl auristatin E
MMAF monomethyl auristatin F
TMCC3 transmembrane and coiled-coil domain family 3
It should be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. As well, the terms “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein. It is also to be noted that the terms “comprising,” “including,” and “having” can be used interchangeably.
Often, ranges are expressed herein as from “about” one particular value and/or to “about” another particular value. When such a range is expressed, an embodiment includes the range from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the word “about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to and independently of the other endpoint. As used herein the term “about” refers to ±20%, ±15%, ±10%, ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, ±1%, ±0.5%, or ±0.25%.
When referring to a formulation component, it is intended that the term used, e.g., “agent,” encompass not only the specified molecular entity but also its pharmaceutically acceptable analogs, including, but not limited to, salts, esters, amides, prodrugs, conjugates, active metabolites, and other such derivatives, analogs, and related compounds.
The general term “sugar” used herein indicates a monosaccharide, for example glucose (Glc), galactose (Gal), mannose (Man) and fucose (Fuc), as well as derivatives of a monosaccharide, such as an amino sugar and a sugar acid, e.g., glucosamine (GlcN), galactosamine (Galn), N-acetylglucosamine (GlcNAc), N-azidoacetylglucosamine (GlcNAZ), N-acetylgalactosamine (GlaNAc), N-acetylneuraminic acid (NeuNAc), N-acetylmuramic acid (MurNAc), glucuronic acid (GlcA), and iduronic acid (IdoA).
As used herein, the term “protein” can include a polypeptide having a native amino acid sequence, as well as variants and modified forms regardless of their origin or mode of preparation. A protein which has a native amino acid sequence is a protein having the same amino acid sequence as obtained from nature. Such native sequence proteins can be isolated from nature or can be prepared using standard recombinant and/or synthetic methods. Native sequence proteins specifically encompass naturally occurring truncated or soluble forms, naturally occurring variant forms (e.g., alternatively spliced forms), naturally occurring allelic variants and forms including post-translational modifications. A native sequence protein includes proteins following post-translational modifications such as glycosylation, or phosphorylation, or other modifications of some amino acid residues.
As used herein, the term “glycoprotein” refers to a protein comprising one or more monosaccharide or oligosaccharide chains covalently bonded to the protein. A glycan may be attached to a hydroxyl group of the protein (O-linked-glycosyl), e.g., to the hydroxy group of serine, threonine, tyrosine, hydroxylysine or hydroxyproline, or to an amide on the protein (N-glycoprotein), e.g., asparagine or arginine, or to a carbon on the protein (C-glycoprotein), e.g., tryptophan. A glycoprotein may comprise more than one glycan, may comprise a combination of one or more monosaccharide and one or more oligosaccharide glycans, and may comprise a combination of N-linked, O-linked and C-linked glycans. Examples of glycoproteins include ligands specific to surface antigens of cells, prostate-specific membrane antigen, candida antarctica lipase, gp41, gp120, erythropoietin (EPO), antifreeze protein and antibodies.
An antibody is a protein generated by the immune system that is capable of recognizing and binding to a specific antigen. The term antibody herein is used in its broadest sense and specifically includes monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g. bispecific antibodies), antibody fragments, and double and single chain antibodies. The term “antibody” is herein also meant to include human antibodies, humanized antibodies, chimeric antibodies and antibodies specifically binding cancer antigen, the term “antibody” is meant to include whole antibodies, but also fragments of an antibody, for example an antibody Fab fragment. F(ab′)2, Fv fragment or Fc fragment from a cleaved antibody, an scFv-Fc fragment, a minibody, a diabody or an scFv. Furthermore, the term includes genetically engineered derivatives of an antibody. Antibodies, fragments of antibodies and genetically engineered antibodies may be obtained by methods that are known in the art. Suitable marketed antibodies include, but are not limited to, abciximab, rituximab, basiliximab, palivizumab, infliximab, trastuzumab, alemtuzumab, adalimumab, tositumomab-1131, cetuximab, ibrituximab tiuxetan, omalizumab, bevacizumab, natalizumab, ranibizumab, panitumumab, eculizumab, certolizumab pegol, golimumab, canakinumab, catumaxomab, ustekinumab, tocilizumab, ofatumumab, denosumab, belimumab, ipilimumab and brentuximab.
Antibodies can be produced using any number of expression systems, including prokaryotic and eukaryotic expression systems. In some embodiments, the expression system is a mammalian cell expression, such as a hybridoma, or a CHO cell expression system. Many such systems are widely available from commercial suppliers. In embodiments in which an antibody comprises both a VH and VL region, the VH and VL regions may be expressed using a single vector, e.g., in a di-cistronic expression unit, or under the control of different promoters. In other embodiments, the VH and VL region may be expressed using separate vectors. A VH or VL region as described herein may optionally comprise a methionine at the N-terminus.
The genes encoding the heavy and light chains of an antibody of interest can be cloned from a cell, e.g., the genes encoding a monoclonal antibody can be cloned from a hybridoma and used to produce a recombinant monoclonal antibody. Gene libraries encoding heavy and light chains of monoclonal antibodies can also be made from hybridoma or plasma cells. Random combinations of the heavy and light chain gene products generate a large pool of antibodies with different antigenic specificity.
Techniques for the production of single chain antibodies or recombinant antibodies (U.S. Pat. Nos. 4,946,778, 4,816,567) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, can be used to express humanized or human antibodies (see, e.g., U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, Marks et al., Bio/Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859 (1994); Morrison, Nature 368:812-13 (1994); Fishwild et al., Nature Biotechnology 14:845-51 (1996); Neuberger, Nature Biotechnology 14:826(1996); and lonberg & Huszar, Intern. Rev. Immunol. 13:65-93 (1995)).
As used herein, “GlcNAc1,” “GlcNAc2,” “GlcNAc3.” an “GlcNAc4” respectively represent the GlcNAc sugars at different positions of an antenna-shaped glycan moiety.
As used herein,
represents a tri-mannosyl structure comparing three mannoses, wherein the first mannose (Man1) links to a GlcNAc sugar; and the second and third mannoses (Man3 and Man3) respectively link to Man1 through α-1,3 and α-1,6 glycosidic linkages.
As used herein, “-(Fuc)0-1” represents that a fucose sugar is optionally existing, and when present, there is only one fucose sugar.
As used herein, “—(CH2)0-8—” represents that —CH2— may or may not exist, and when present, it may independently be 1, 2, 3, 4, 5, 6, 7 or 8 —CH2— groups.
One aspect of the invention provides a process for producing a glycoprotein-payload conjugate comprising a structure of formula (1):
with β-N-acetylglucosaminidase to produce a modified glycoprotein comprising a tri-mannosyl core of formula (3)
is formed; and
In some embodiments, the two payloads are different, the payloads can be attached to any of the four Man-GlcNAc structures in the glycoprotein in a random manner.
Another aspect of the invention provides a process for producing a glycoprotein-payload conjugate comprising a structure of formula (5):
is formed; and
In some embodiments, in order to precisely control the positions of the payloads attached, a glycoprotein-payload A/B conjugate comprising a structure of formula (7)
can be produced by the following steps:
is formed; and
Glycoproteins as used herein may be obtained, for example, by solid-state peptide synthesis (e.g. Merrifield solid phase synthesis) or recombinant production. For recombinant production one or more polynucleotide encoding the glycoprotein is isolated and inserted into a vector for further cloning and/or expression in a host cell. Such polynucleotide may be readily isolated and sequenced using conventional procedures. Methods which are well known to those skilled in the art can be used to construct expression vectors containing the coding sequence of the glycoprotein. These methods include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See, for example, the techniques described in Maniatis et at., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory. N.Y. (1989); and Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Associates and Wiley Interscience, N.Y. (1989).
As used herein, β-N-etylglucosaminidase represents a glycosidase family that catalyzes the hydrolysis of β-N-Acetylglucosamine residues from oligosaccharides. Many β-N-Acetyl-glucosaminidases have been found to have board hydrolysis ability in catalyzing multiple types of β-glycosidic linkage. In a preferred embodiment the β-N-acetylglucosaminidase may be an exoglycosidase which is capable of hydrolysizing beta 1-2 linkage located between terminal acetylglucosamine residues and N-glycan of a glycoprotein. Exo-β-N-acetylglucosaminidase variants can be obtained from different sources, such as Streptococcus spp. and Canavalia ensiformis.
According to the invention, mannosyl (α-1,3-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase (MGAT1; GnT-I; EC:2.4.1.101) transfers N-acetyl-D-glucosamine from UDP-GlcNAc to a terminal mannose which is linked to another sugar moiety or glycan through alpha 1-3 glycosidic linkage. The linkage of GlcNAc and alpha 3 mannose transferred by MGAT1 is a β1-2 glycosidic bond. It has been found that MGAT1 is universally expressed in eukaryote because it is an essential enzyme to hybrid and complex N-glycan biosynthesis in Golgi.
According to the invention, mannosyl (α-1,6-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase (MGAT2; GnT-II; EC 2.4.1.143) transfers N-acetyl-D-glucosamine from UDP-GlcNAc to a terminal mannose which is linked to another sugar moiety or glycan through alpha 1-6 glycosidic linkage. The linkage of GlcNAc and alpha 6 mannose transferred by MGATII is beta 1-2 glycosidic bond. It has been found that MGAT2 is universally expressed in eukaryote because it ts an essential enzyme for complex N-glycans biosynthesis in Golgi.
In some embodiments, the reaction between the glycoprotein comprising the glycan having formula (2) and β-N-acetylglucosaminidase is performed in a mammalian cell culture. In the mammalian cell culture, a mammalian cell line, which comprises a first polynucleotide encoding the the glycoprotein comprising the glycan having formula (2), and a second polynucleotide encoding the β-N-acetylglucosaminidase, is incubated in a medium at a condition suitable for expression of the glycoprotein and the β-N-acetylglucosaminidase. Examples of mammalian host cell lines include monkey kidney CV1 line transformed by SV40 (COS-7), human embryonic kidney line (293 or 293T cells), baby hamster kidney cells (BHK), mouse sertoli cells (TM4 cells), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK), buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (Hep G2), mouse mammary tumor cells (MMT 060562), TRI cells, MRC 5 cells, FS4 cells, Chinese hamster ovary (CHO) cells, and myeloma cell lines such as YO, NS0, P3X63 and Sp2/0.
In some embodiments of the invention, the glycoprotein is an antibody or fragments thereof. The antibody or fragments thereof can be antibody Fab fragment, F(ab′)2. Fv fragment or Fc fragment from a cleaved antibody, an scFv-Fc fragment, a minibody, a diabody or an scFv. In a preferred embodiment, the antibody is Herceptin, trastuzumab or an anti-TMCC3 antibody.
In an embodiment of the invention, when R is azido (is this normal name!), and the conjugator is alkynyl, the conjugator-linker-payload reacts with -GlcNAc-(CH2)0-8—R group to form -GlcNAc-(CH2)0-8-linker-payload through click reaction (Angewandle Chemie International Edition. 40 (11): 2004-2021; and Australian Journal of Chemistry. 60 (6): 384-395). In another embodiment, when R is an a ketone group or an aldehyde, and the conjugator is amino, the conjugator-linker-payload reacts with -GlcNAc-(CH2)0-8—R group to form -GlcNAc-(CH2)0-8-linker-payload through reductive amination (J. Org. Chem., 2010, 75, 5470-5477; and Synthesis, 2011, 490-496) In a further embodiment, when R is an a ketone group or an aldehyde, and the conjugator is β-arylethylamino, the conjugator-linker-payload reacts with the -GlcNAc-(CH2)0-8—R group to form -GlcNAc-(CH2)0-8-linker-payload through Pictet-Spengler reaction (Bioconjugate Chem., 2013, 24 (6), pp 846-851).
In some embodiments, when the glycoprotein-payload conjugate is used for treatment of a disease in a subject, the payload may be a therapeutic agent. The therapeutic agent can be a cytostatic or cytotoxic agent or an isotope-chelating agent with corresponding radioisotopes. Examples of the cytostatic or cytotoxic agent include, without limitation, antimetabolites (e.g., fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate, leucovorin, hydroxyurea, thioguanine (6-TG), mercaptopurine (6-MP), cytarabine, pentostatin, fludarabine phosphate, cladribine (2-CDA), asparaginase, gemcitabine, capecitibine, azathioprine, cytosine methotrexate, trimethoprim, pyrimethamine, or pemetrexed); alkylating agents (e.g., cmelphalan, chlorambucil, busulfan, thiotepa, ifosfamide, carmustine, lomustine, semustine, streptozocin, dacarbazine, mitomycin C, cyclophosphamide, mechlorethamine, uramustine, dibromomannitol, tetranitrate, procarbazine, altretamine, mitozolomide, or temozolomide); alkylating-like agents (e.g., cispiatin, carboplatin, nedaplatin, oxaliplatin, satraplatin, or triplatin); DNA minor groove alkylating agents (e.g., duocarmycins such as CC-1065, and any analogs or derivatives thereof; pyrrolobenzodiazapenes, or any analogs or derivatives thereof); anthracyclines (e.g., daunorubicin, doxorubicin, epirubicin, idarubicin, or valrubicin); antibiotics (e.g., dactinomycin, bleomycin, mithramycin, anthramycin, streptozotocin, gramicidin D, mitomycins (e.g., mitomycin C); calicheamicins; antimitotic agents (including, e.g., maytansinoids (such as DM1, DM3, and DM4), auristatins (including, e.g., monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF)), dolastatins, cryptophycins, vinca alkaloids (e.g., vincristine, vinblastine, vindesine, vinorelbine), taxanes (e.g., paclitaxel, docetaxel, or a novel taxane), tubulysins, and colchicines); topoisomerase inhibitors (e.g., irinotecan, topotecan, camptothecin, eloposide, teniposide, amsacrine, or mitoxantrone); HDAC inhibitor (e.g., vorinostat, romidepsin, chidamide, panobinostat, or belinostat); proteasome inhibitors (e.g., peptiyl boronic acids), as well as radioisotopes such as At211, I131, I125, Y90, Re186, R188, Sm153, Bi212 or 213, P32 and radioactive isotopes of Lu including Lu177. Examples of the isotope-chelating agents include, without limitation, ethylenediaminetetraacetic acid (EDTA), diethylenetriamine-N,N,N′,N″,N′″-pentaacetate (DTPA), 1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetate (DOTA), 1,4,7,10-tetrakis(2-hydroxypropyl)-1,4,7,10-tetraazacycloododecane (THP), triethylenetetraamine-N,N,N′,N″,N″′,N′″-hexaacelate (TTHA), 1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetrakis(methylenephosphonate) (DOTP), and mercaptoacetyltriglycine (MAG3).
In some embodiments, when the glycoprotein-payload conjugate is used for detection, the pas load may be a label. The labels include, but are not limited to, labels or moieties that are detected directly (such as fluorescent, chromophoric, election-dense, chemiluminescent, and radioactive labels), as well as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through an enzymatic reaction or molecular interaction. Exemplary labels include, but are not limited to, the radioisotopes P32, C14, I125, H3, and I331, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterial luciferase, luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, and the like. In another embodiment, a label is a positron emitter. Positron emitters include but are not limited to Ga68, F18, Cu64, Y86, Br76, Zr89, and I124.
In some embodiments, the linker has a functionality that is capable of reacting with an electrophilic group present on a glycoprotein. Examples of such electrophilic groups include, but are not limited to, aldehyde and ketone carbonyl groups. In some embodiments, a heteroatom of the reactive functionality of the linker can react with an electrophilic group on a glycoprotein and form a covalent bond to a glycoprotein unit. Nonlimiting examples of such reactive functionalities include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.
In some embodiments, the conjugator has a functionality that is capable of reacting with an electrophilic group present on a glycoprotein. Examples of such electrophilic groups include, but are not limited to, azide, aldehyde and ketone groups. In some embodiments, a heteroatom of the reactive functionality of the conjugator can react with an electrophilic group on a glycoprotein and form a covalent bond to a glycoprotein unit. Nonlimiting examples of such reactive functionalities include, but are not limited to, alkyne, dibenzocyclooctyne, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.
In some embodiments, the linker has a functionality that is capable of connecting conjugator and payload. Examples of such linkers include, but are not limited to, non-cleavable linkers and cleavable linkers. In some embodiments, non-cleavable linkers include, but are not limited to linear or branched alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, alkoxy, acyl, alkylamines, or arylamine group having 2 to 20 carbon atoms. In some embodiments, cleavable linkers include, but are not limited to disulfide containing linkers, acid labile linkers, photolabile linkers, peptidase labile linkers, and esterase labile linkers
The following examples are presented to illustrate certain embodiments of the present invention, but should not be construed as limiting the scope of this invention. The scope of this invention includes a one step or a sequential process to generate a homogenous ADC with one species or dual species of payloads from a tri-mannosyl core antibody as shown in
In order to remove glactose and sialic acid moieties of the N-glycan from Herceptin antibody (Roche Inc), 10 mg of Herceptin antibody was treated with 20 μl β1,4-Galactosidase (NEB, P0745L, 8 unit/μl) and 5 μl α2-3,6,8 neuraminidase (NEB, P0720L, 50 unit/μl) in 1× GlycoBuffer 1 (NEB, total volume 1 ml) at 37° C. for 24 hours. 10 μl of β1,4-Galactosidase (NEB, P0745L, 8 unit/μl) was further added to the reactant and the reaction was allowed to perform at 37° C. for further 24 hours to obtain a G0F/G0 antibody sample. The antibody sample was purified by using rProtein A Sepharose Fast Flow (GE Healthcare, 17-1270-02). After purification, the antibody sample was subjected to reduced mass chromatography analysis. The results shown in
10 mg of G0F/G0 Hercepin antibody from Example 1 was treated with 20 μl β-N-Acetylglucosaminidase S (NEB, P0744L, 4 unit/μl) in 1× GlycoBuffer 1 (NEB, total volume 1 ml) at 37° C. for 24 hours. 10 μl of β-N-Acetylglucosaminidase S (NEB, P0744L, 4 unit/μl) was added to the reactant and the reaction was allowed to proceed at 37° C. for further 24 hours to obtain a digested antibody sample. The digested antibody sample was purified by using rProtein A Sepharose Fast Flow (GE Healthcare, 17-1279-02). After purification, the antibody sample was subjected to reduced mass chromatography analysis. The results shown in
Tri-mannosyl core Herceptin antibody (40 μg) from Example 2 and UDP-GlcNAc (final concentration of 2.5 mM) (Sigma, U4375) in 80 μl 1× buffer SP (25 mM MES (4-morpholineethanesulfonic acid), 10 mM MnCl2, pH 6.5) were incubated in the presence of MGAT-1 (0.15 μg; R&D, 8334-GT) at 37° C. for 16 hours. The product was subjected lo a Reduced Mass Chromatographs analysis. As the results shown in the
Tri-mannosyl core Herceptin antibody (40 μg) from Example 2 and UDP-GlcNAc (final concentration of 2.5 mM) (Sigma, U4375) in 80 μl 1× buffer SP (25 mM MES, 10 mM MnCl2, pH 6.5) were incubated in the presence of MGAT-1 (0.15 μg) and MGAT-2 (0.1 μg) at 37° C. for 16 hours. After the incubation, the reaction product was subjected to a reduced mass chromatography analysis. As the results shown in the
MGAT-2 transfers a GlcNAc sugar from UDP-GlcNAc to α(1,6) mannose of the tri-mannosyl core only when the tri-mannosyl core already has a GlcNAc sugar linked to α(1,3) mannose. In other words, if no GlcNAc sugar is linked to α(1,3) mannose of the tri-mannosyl core, MGAT-2 will be unable to transfer a GlcNAc sugar to either α(1,3) mannose or α(1,6) mannose. To confirm the above observation, tri-mannosyl core Herceptin antibody (40 μg) from example 2 and UDP-GlcNAc (2.5 mM) in 80 μl 1 × buffer SP (25 mM MES, 10 mM MnCl2, pH 6.5) were incubated in the presence of MGAT-2 (0.1 μg) at 37° C. for 16 hours. The product was subjected to a reduced mass chromatography analysis. There is no significant change to molecular weight of the tri-mannosyl core antibody in the mass spectrum (data not shown). This result suggests that the tri-mannosyl core is not a substrate of MGAT-2, and that MGAT-2 needs the conversion product of MGAT-1 to generate a G0F/G0 type antibody.
Tri-mannosyl core Herceptin antibody (40 μg) from Example 2 and UDP-GlcNAz (1 mM) (R&D, ES104-100) in 80 μl 1× buffer (20 mM Tris, 10 mM MnCl2, pH 6.5) were incubated in the presence of MGAT-1 (0.25 μg; R&D, 8334-GT) at 37° C. for 16 hours. The product was subjected to a Reduced Mass Chromatography analysis. As the results shown in the
Tri-mannosyl core Herceptin antibody (2 mg) from Example 2 and UDP-GlcNAz (1 mM) in 800 μl 1× buffer SP (25 mM MES, 10 mM MnCl2, pH 6.5) were incubated in the presence of rabbit MGAT-1 (25 μg) and rat MGAT-2 (10 μg) at 37° C. for 16 hours. After the incubation, the reaction product was subjected to a Reduced Mass Chromatography analysis and an Intact Mass Chromatography analysis, respectively. As the Reduced Mass Chromatography results shown in the
Tri-mannosyl core Herceptin antibody (40 μg) from Example 2 and UDP-GlcNAz (1 mM) (R&D ES104-100) in 80 μl 1× buffer SP (25 mM MBS, 10 mM MnCl1, pH 6.5) were incubated in the presence of rat MGAT-2 (0.25 μg) at 37° C. for 16 hours. The product was subjected to a Reduced Mass Chromatographs analysis.
In Example 7, a tri-mannosyl antibody with each of 4 GlcNAz attached at 4 terminal mannoses was produced. To complete one-step process hypothesis of this invention, DBCO-(PEG)4-DM1 was used to couple a toxic payload to the tri-mannosyl Herceptin-4GlcNAz to generate a ADC with DAR4. 5 μL of DBCO-(PEG)4-DM1 (10 mM in DMSO) was slowly added to 50 μL buffer (25 mM MES; pH 6.5) containing 5 mg/mL tri-mannosyl-4GlcNAz Herceptin antibody obtained from Example 7 to perform a click chemistry reaction at 25° C. for overnight. After reaction, the antibody product was purified through Amicon Ultra-15 centrifugal filter device to obtain tri-mannosyl Herceptin-4(GlcNAc-triazole-DBCO-(PEG)4-DM1)ADC. The product was subjected to a Reduced Mass Chromatography analysis. The result in
Examples 4 to 9 support the feasibility of one-step process for ADC generation in this invention to generate a site-specific ADC with homogenous DAR of 4. With these successful results, a study was performed to prove the sequential process shown in
The tri-mannosyl Herceptin-2GlcNAz-2(GlcNAc-triazole-DBCO-(PEG)4-DM1) obtained from Example 10 and UDP-GlcNAz (1 mM) (R&D ES104-100) in 500 μl 1× buffer (25 mM MES, 10 mM MnCl2, pH 6.5) were incubated in the presence of rat MGAT-2 (15 μg) at 37° C. for 16 hours. After reaction, the antibody product was filtrated through Amicon Ultra-15 centrifugal filter device to obtain tri-mannosyl Herceptin-2GlcNAz-2(GlcNAc-triazole-DBCO-(PEG)4-DM1). The product was subjected to a Reduced Mass Chromatography analysts. As the results shown in the
In Example 11, a tri-mannosyl Herceptin-2GlcNAz-2(GlcNAc-triazole-DBCO-(PEG)4-DM1) intermediate was produced. To complete the sequential process of this invention shown in
3.8 μL of DBCO-(PEG)12-MMAE (10 mM in DMSO) was slowly added to 76 μL 1× buffer (25 mM MES, pH 6.5) containing 2.5 mg/ml tri-mannosyl Herceptin-2GlcNAz-2(GlcNAc-triazole-DBCO-(PEG)4-DM1) ADC obtained from Example 11. The reaction mixture was stirred under argon at 25° C. overnight to preform a click chemistry reaction. After the reaction, the antibody product was filtrated through Amicon Ultra-15 centrifugal filter device to obtain tri-mannosyl Herceptin-2(GlcNAc-triazole-DBCO-(PEG)4-DM1)-2(GlcNAc-triazole-DBCO-(PEG)12-MMAE) ADC. After the purification, the product was then subjected to an intact mass chromatography analysis. As the results shown in the
3.8 μL of DBCO-MMAF (10 mM in DMSO) was slowly added to 76 μL 1× buffer (25 mM MES, pH 6.5) containing 2.5 mg mL tri-mannosyl Herceptin-2GlcNAz-2(GlcNAc-triazole-DBCO-(PEG)4-DM1) ADC obtained from Example 11. The reaction mixture was stirred under argon at 25° C. overnight to perform a click chemistry reaction. After the reaction, the antibody product was nitrated through Amicon Ultra-15 centrifugal filter device to obtain tri-mammosyl Herceptin-2(GlcNAc-triazole-DBCO-(PEG)4-DM1)-2(GlcNAc-triazole-DBCO-MMAF) ADC. The product was subjected to an intact mass chromatography analysis. As the results shown in the
In summary, by combining MGAT-1, MGAT-2, and GlcNAz enzymatic reactions and DBCO-payload chemistry reactions, we rationalize our hypothesis of the invention. We are able to generate a homogenous site-specific ADC product with DAR4 or DAR2 by our one-step process. On the other hand, the invention is also applied to synthesize a homogenous site-specific ADC product with dual species of payloads by the sequential process.
A tri-mannosyl Herceptin-4(GlcNAc-triazolo-DBCO-(PEG)4-DM1) ADC was constructed by the processes described above. Kadcyla against Her2/Neu molecule was purchased from (Roche Inc). ERBB2-ECD (ebioscience BMS362) (100 ng/well) was added to each well of a NUNC Maxisorp plate and the plate was set aside at 4° C. overnight. The plate was w ashed with 1× PBS-T (0.1%) to remove the uncoated reagent. 3% skim milk was added to the wells of the plate, and the plate was set aside at room temperature for 2 hours. The plate was washed with 1× PBS-T (0.1%) for 3 times, was allowed to dry and then was stored at −20° C. for further use. A series of dilutions from 1×10−6 g/mL to 1×10−12 g/mL of individual antibodies were added to the plate, and the plate was incubated at 370 C for 1 hour. A goat anti-human IgG conjugated with horseradish peroxidase (HRP) was added for 1 hour incubation, and then 3,3′,5,5′-Tetramethylbenzidine (TMB) was added. The OD405 was read to calculate the activity. Every study was repeated three times, and the data were presented as mean ±SD. OD readings and concentrations of antibodies were used to make a multiple scatter plot using Prism software. The results shown in
Her2/Neu high-expression cell line SK-BR-3, Her2/Neu medium-expression cell line HCC-1954 and Her2/Neu low-expression cell line MDA-MB-231 were diluted to 106 cells/ml. After adding 100 μL of the diluted cell culture to the wells of a 96-well plate, the cells were incubated at 37° C. for 24 hours. 80 μl complete medium was added to each well, and 20 μl tri-mannosyl Herceptin-4(GlcNAc-triazole-DBCO-(PEG)4-DM1) ADC in different doses wits then added to different wells. After the plate being incubated at 37° C. for 48 hours. 100 μl the CellTiter-Glo® Reagent was added to each wells. After further incubation for 10 minutes at room temperature, luminescence (light) of the wells was measured by a lummomeler. The IC50 values of tri-mannosyl Herceptin-4(GlcNAc-triazole-DBCO-(PEG)4-DM1) ADC to Her2/Neu high-expression cell line SK-BR-3, and Her2/Neu medium-expression cell line HCC-1954 were 4.7 nM and 14 nM, respectively. The IC50 values also show that all the antibodies tested had no anti-proliferation effects on the Her2/Neu low-expression cell line MDA-MB-231. This result suggests that as Kadcyla, the tri-mannosyl Herceptin-4(GlcNAc-triazole-DBCO-(PEG)4-DM1) ADC docs not only have cytoxicity to the Her2/Neu high expressing cells, but also the Her2/Neu medium expressing medium-expression cells and the modification of antibody by tri-mannosyl ADC platform does not affect the its biological activity.
A plasmid pTCAH8.3-exo-Gal containing a cDNA encoding β-N-acctylglucosaminidase S was constructed and co-transfected into two F293 cell lines to express tri-mannosyl trastuzumab (an anti-Her2 antibody) and tri-mannosyl anti-TMCC3 (transmembrane and coiled-coil domain family 3) antibody, respectively. After incubation, the supernatants of the two cell cultures were collected and the antibodies contained therein were purified by using rProtein A Sepharose Fast Flow (GE Healthcare, 17-1279-02), respectively. After purification, the purified antibody samples were subjected to Reduced Mass Chromatography Analysis. The results shown in
According to the processes described in Example 7, 2 mg of tri-mannosyl core trastuzumab antibody (produced by mammalian cells) obtained from Example 16 and UDP-GlcNAz (1 mM) in 800 μl 1× buffer SP (25 mM MES, 10 mM MnCl2, pH 6.5) were incubated in the presence of rabbit MGAT-1 (25 μg) and rat MGAT-2 (10 μg) at 37° C. for 16 hours. After the incubation, the reaction product was subjected to a reduced mass chromatography analysis and an intact mass chromatography analysis. As the reduced mass chromatography results shown in the
According to the processes described in example 9, DBCO-)PEG)4-DM1 was slowly added to Tris buffer (pH 7.0) containing tri-mannosyl trastuzumab-4GlcNAz antibody obtained above to perform a click chemistry reaction at 25° C. for 16 hours. After reaction and purification, the product was subjected to a reduced mass chromatography analysis and an Intact Mass Chromatographs analysis. The Reduced Mass Chromatography analysis results in
One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described herein, as presently representative of preferred embodiments, are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.
This application claims the benefit of U.S. Provisional Patent Application No. 62/440,075, filed on 29 Dec. 2016, the entire content of which is incorporated by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2017/068872 | 12/29/2017 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62440075 | Dec 2016 | US |
